Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.

International journal of medical sciences - 1 Jan 2013

Antonicelli Alberto, Cafarotti Stefano, Indini Alice, Galli Alessio, Russo Andrea, Cesario Alfredo, Lococo Filippo Maria, Russo Patrizia, Mainini Alberto Franco, Bonifati Luca Giuseppe, Nosotti Mario, Santambrogio Luigi, Margaritora Stefano, Granone Pierluigi Maria, Dutly André Emanuel

Abstract excerpt

The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 23423768
DOI: 10.7150/ijms.4609
PMCID: PMC3575628

Genes

EGFR
ALK
EML4
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.PMID 23423768Read ↗

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.Semantic proximity Read ↗

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.Semantic proximity Read ↗

EGFR signaling pathway as therapeutic target in human cancers.Semantic proximity Read ↗

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.Semantic proximity Read ↗

Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.Semantic proximity Read ↗

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact.Semantic proximity Read ↗

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.Semantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.Semantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary managementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.